QMS Evidence for Kenya Device Registration: Accepted Forms and Equivalence

Content verified as of 30 October 2026.

1. Key takeaways

• Kenya takes an approach of equivalency recognition for quality management system (QMS) evidence rather than a single mandatory form: acceptable evidence includes an ISO 13485 certificate, a free sale certificate evidencing compliance with the US QSR, proof under Japanese MHLW Ordinance No. 169, a declaration of adequate QMS, and a CE certificate from the EU, UK or Ireland.
• Within the 9 items for a Class A listing, item ⑨ is the QMS evidence; Class B/C/D follow the technical evidence route, but establishment registration still requires an established quality management system with the QMS manual and procedures submitted electronically.
• Establishment registration carries its own thresholds: Class C or D establishments must provide pre-market approval or registration evidence from at least one IMDRF member regulatory authority, or confirmation of WHO prequalification; Class B/C/D establishments must provide a certificate of free sale (CFS) from the country of manufacture or final assembly.
• Equivalency is not exemption from scrutiny. Section 3B(2)(r) of the Pharmacy and Poisons Act empowers PPB to recognise and rely on the decisions of other authorities, while expressly leaving PPB responsible for its own decisions.
• Annual retention must be applied for on Form 4 with a copy of a valid GMP certificate; the validity of QMS certificates is tied directly to retention and renewal.

2. Legal basis

3. Expert insights

Insight 1: Five forms of evidence sit side by side, but their evidentiary weight is graded. The guidelines list the five forms together, yet in practice they are not equally credible. Third-party certified ISO 13485 certificates and CE certificates are issued by independent bodies and can be verified directly; the free sale certificate evidencing compliance with the US QSR and proof under Japanese MHLW Ordinance No. 169 are conclusive documents from regulatory authorities and carry equally high weight; a declaration of adequate QMS is the manufacturer’s self-declaration and is a fallback channel. GRZAN’s judgement: the self-declaration is usable in a Class A listing but will almost certainly trigger supplementary requirements for Class C/D, because establishment registration for C/D already demands approval from an IMDRF member regulatory authority or WHO prequalification. Treating the fallback option as the routine option is the most common misjudgment seen in this module.

Insight 2: The equivalency argument should be a mapping table, not a certificate handed over. PPB may rely on the conclusions of other authorities under Section 3B(2)(r), but reliance presupposes comparability. GRZAN recommends a short equivalency argument: the left column lists clauses of ISO 13485 or 21 CFR 820; the right column lists the corresponding procedure document numbers and sections in the manufacturer’s quality manual. The table need not be long and is generally not required in EU or US submissions, yet in Kenya it markedly reduces deficiency requests asking how the system covers design controls, purchasing controls or corrective and preventive action, often saving an entire round of inquiries.

Insight 3: Validity alignment is an underrated point of failure. Annual retention must attach a copy of a valid GMP certificate; the system opens for submission 60 days before the annual fee falls due, and the process should be completed 3 months before year end; renewal is applied for on Form 4 and requires retention fees to have been paid in full. If a QMS or GMP certificate falls into a recertification gap inside the retention window, retention stalls, which in turn affects renewal eligibility. GRZAN recommends scheduling the certification body’s recertification audit early so that every annual retention submission within the 5-year certificate period is covered.

4. Practical recommendations

1. Match evidence strength to risk class. Class A may rely on ISO 13485; for Class C/D prioritise third-party certificates plus an IMDRF member regulatory authority approval, avoiding fallback on a self-declaration.
2. Prepare an equivalency mapping table. With GRZAN support, map system clauses to internal procedure documents one by one and submit it as an annex to the QMS module.
3. Leave lead time for recertification. Schedule the certification body’s recertification audit before the annual retention window so a valid GMP certificate copy is always available.
4. Prepare the CFS and the original approval in parallel. Class B/C/D establishment registration requires a CFS, and Class C/D additionally requires an IMDRF member regulatory authority approval or WHO prequalification; these can run alongside the registration submission.
5. Keep a certificate expiry ledger. Register the expiry dates of QMS, GMP, CFS and CE certificates in one place with advance reminders.
6. Watch the effect of institutional change on the reliance route. Once the planned Kenya Health Products and Technologies Regulatory Authority (KHPTA) takes over PPB’s functions, the evidentiary standard for reliance may be adjusted (the Act had not completed the full legislative process as of the verification date; this is a practical estimate).

5. Verification checklist

• □ Has a form of QMS evidence been selected (ISO 13485, US QSR, MHLW Ordinance No. 169, declaration of adequate QMS, or CE certificate)?
• □ Does the selected evidence cover the full product scope and all manufacturing sites intended for registration?
• □ Has an equivalency mapping table of system clauses to internal procedures been prepared?
• □ For Class C/D, has approval from at least one IMDRF member regulatory authority or WHO prequalification been obtained?
• □ For Class B/C/D, has a CFS from the country of manufacture or final assembly been obtained?
• □ Do the QMS and GMP certificate validity periods cover each annual retention submission within the 5-year certificate period?
• □ Is there an expiry ledger with advance reminders for QMS, GMP, CFS and CE certificates?
• □ Is the GMP certificate copy attached to annual retention Form 4 the latest version?

Regulatory information verified as of 30 October 2026.

In African markets, the GRZAN regulatory team focuses on jurisdictions such as Kenya, Nigeria, South Africa and Egypt and maintains a verification mechanism built on primary regulatory sources. Every regulatory conclusion it issues rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, with the verification date stated; any figure, timeline or amount that cannot be located in an official source is marked as a practical estimate and is never presented as presumption.

GRZAN services cover market access strategy and risk classification; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of local authorized representatives (LARs); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import clearance and PVoC coordination; regulatory intelligence subscriptions and corporate compliance ledgers.

For a Kenya market access plan for a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.